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Abstract
Objectives:
Abstract
Diabetes impairs fracture healing. Our laboratory previously suggested that a dominant mechanism was the
premature loss of cartilage during endochondral bone formation. Based on these results we tested the
hypothesis that chondrocytes regulate osteoclast formation in diabetes-impaired fracture healing and that it is
controlled by the transcription factor FOXO1.
Methods:
Closed fracture of the femur was induced in mice with lineage-specific FOXO1 deletion in chondrocytes
Col2α1Cre+/FOXO1L/L and Col2α1Cre-/ FOXO1L/L as control mice that had FOXO1 gene present. Mice
were rendered diabetic by multiple streptozotocin injections. The normoglycemic group received vehicle
alone. Specimens were collected at 10 days (cartilage formed), 16 days (transition from cartilage to bone
formation) and 22 days (primary bone formed). The cartilage area was measured using safranin-O/fast green
staining. Osteoclasts were counted as TRAP positive cells. The expression of cathepsin K and RANKL were
determined by quantitative immunostaining with specific antibodies compared to control IgG. Micro CT was
used to measure the callus volume and the mineralized bone. Statistical analysis was done using a one-way
ANOVA test. Results with p
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Results:
All the groups showed similar cartilage areas at day 10. At day16 the diabetic group had 77% less cartilage area
than the normal (P
Conclusion:
Our data indicates that FOXO1 drives RANKL expression in chondrocytes and resorption of cartilage.
FOXO1 deletion reverses diabetes-enhanced osteoclast formation and prevents the premature loss of
cartilage, which results in a better bone healing.
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Abstract  
Objectives:  
Diabetes impairs fracture healing. Our laboratory previously suggested that a 
dominant mechanism was the premature loss of cartilage during endochondral 
bone formation. Based on these results we tested the hypothesis that 
chondrocytes regulate osteoclast formation in diabetes-impaired fracture 
healing and that it is controlled by the transcription factor FOXO1.  
Methods:  
Closed fracture of the femur was induced in mice with lineage-specific FOXO1 
deletion in chondrocytes Col2α1Cre+/FOXO1L/L and Col2α1Cre-/ FOXO1L/L as 
control mice that had FOXO1 gene present. Mice were rendered diabetic by 
multiple streptozotocin injections. The normoglycemic group received vehicle 
alone. Specimens were collected at 10 days (cartilage formed), 16 days 
(transition from cartilage to bone formation) and 22 days (primary bone 
formed). The cartilage area was measured using safranin-O/fast green 
staining. Osteoclasts were counted as TRAP positive cells. The expression of 
cathepsin K and RANKL were determined by quantitative immunostaining with 
specific antibodies compared to control IgG. Micro CT was used to measure 
the callus volume and the mineralized bone. Statistical analysis was done 
using a one-way ANOVA test. Results with p<0.05 were considered 
significant.  
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Results:  
All the groups showed similar cartilage areas at day 10. At day16 the diabetic 
group had 77% less cartilage area than the normal (P <0.05). The accelerated 
cartilage loss in the diabetic group was completely reversed when FOXO1in 
chondrocytes was deleted (P<0.05). Diabetic mice had 4.4 times more 
cathepsin K positive cells in comparison to normal littermates. This change 
could be accounted for by changes in RANKL expression, which was 2-fold 
greater in the diabetic mice, compared to the normal mice (P <0.05). However, 
when FOXO1 in chondrocytes was deleted in the diabetic animals, osteoclasts 
numbers were reduced to normal levels (P <0.05). Bone volume in the diabetic 
group was 29% and 34% less than the normoglycemic animals on day 16 and 
day 22 respectively (P <0.05). However, the effect of diabetes was rescued to 
normal levels upon FOXO1 deletion in chondrocytes (P <0.05).  
Conclusion:  
Our data indicates that FOXO1 drives RANKL expression in chondrocytes and 
resorption of cartilage. FOXO1 deletion reverses diabetes-enhanced 
osteoclast formation and prevents the premature loss of cartilage, which 
results in a better bone healing.  
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Introduction 
Normal Fracture Healing: 
Long bone fracture healing is a dynamic process that involves complex 
and coordinated activities of stem cells, inflammatory cells, chondrocytes, 
osteoblasts, osteoclasts, and other cell types. (L. Gerstenfeld, Cullininane, 
Barnes, Graves, & Einhorn, 2003). This occurs via two dynamic interactive 
responses. The first is the intramembranous bone formation, which is 
characterized by direct bone formation without using cartilage as a template. 
The periosteum is the primary source of cells involved in this phase. Those 
cells are predominantly osteoprogenitor and undifferentiated mesenchymal 
cells (Einhorn, 1998). The second is the endochondral bone formation. 
Endochondral bone formation is a process that involves recruitment, 
proliferation, and differentiation of undifferentiated mesenchymal stem cells 
into cartilage producing chondrocytes (Einhorn, 1998). Cartilage is eventually 
calcified, resorbed and replaced by bone.  
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Figure1: Long bone fracture healing stages. The callus primarily consists of 
hematoma and immune cells at the inflammatory phase, un-calcified 
cartilaginous soft callus at the second phase, calcified intermixed hard callus, 
and finally the remodeling phase at which the callus will remodel to restore the 
original morphology. 
The fracture healing process can be divided into three interconnected 
phases, initial inflammatory phase, regenerative phase, and finally a 
remodeling phase. Like most other injuries, at the initial phase an inflammatory 
process will start and a hematoma will form from blood cells extravasating the 
damaged blood vessels. Those cells will produce cytokines, which will 
increase the blood capillary permeability (Einhorn, 1998). In addition to the 
blood cells, this phase involves the infiltration of different inflammatory cells 
including macrophages. Macrophages release various cytokines and 
chemokines that help to recruit other inflammatory cells, enhance the 
angiogenesis, and finally promote matrix formation. (Einhorn, Majeska, Rush, 
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Levine, & Horowitz, 1995; L. C. Gerstenfeld et al., 2003). Furthermore, at this 
early stage platelets play a primary role in the initial healing phase. They 
aggregate and are considered a major source of platelet-derived growth factor 
(PDGF) and transforming growth factor-β (TGF-β) that are important for both 
the recruitment and the differentiation of mesenchymal stem cells (Bolander, 
1992). Bone-marrow-derived MSCs differentiate to either cartilage forming 
chondrocytes or bone forming osteoblasts; both of which are critical for 
endochondral ossification of fractured calluses. MSCs mediate and enhance 
angiogenesis in addition to their role in reducing inflammation and apoptosis. 
(Caplan & Dennis, 2006; Cho, Gerstenfeld, & Einhorn, 2002; Shea, Edgar, 
Einhorn, & Gerstenfeld, 2003) . 
The initial stability of the fractured segments is provided by the cartilage. 
Chondrocytes will populate the fracture area and will deposit soft matrix that 
constitutes the soft callus. Those chondrocytes express type II collagen in 
addition to aggrecan which is a significant feature of mature chondrocytes 
(Sandberg, Aro, Multimaki, Aho, & Vuorio, 1989). Chondrocytes will then 
release growth factors and cytokines that induce osteogenesis (L. C. 
Gerstenfeld et al., 2002). Chondrocytes will then differentiate into a 
hypertrophic phase characterized by expressing type X collagen (Barnes, 
Kostenuik, Gerstenfeld, & Einhorn, 1999). Cartilage matrix undergoes 
degradation by collagenases and proteases, predominantly MMP and 
disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin-
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type 1 motifs (ADAMTs). Cartilage degradation and breakdown facilitate the 
formation and the invasion of new blood vessels via VEGF and angiopoietin 
dependent pathways that facilitate the recruitment of osteoclasts and 
osteoblasts (Peng et al., 2005). RANKL also induces the production of 
chemokines, suggesting an amplification loop during recruitment of precursors 
and differentiation of osteoclasts [12]. Little attention was given to 
chondrocytes as a source of RANKL in the literature. Martínez-Calatrava, 
Maria J., et al. looked at the expression of RANKL in chronic arthritis rabbit 
model. They have found that chondrocytes had very high RANKL expression 
in the osteoarthritis group and the expression of RANKL was proportional to 
the articular bone loss observed in that group.(Martinez-Calatrava et al., 2012) 
The apoptosis phase of the hypertrophic chondrocytes is a critical 
phase during fracture repair (F. Y. Lee, Choi, Behrens, DeFouw, & Einhorn, 
1998; Li, White, Connolly, & Marsh, 2002). There is a direct relationship 
between the vasculature and the rate of apoptosis and resorption of cartilage. 
This process is mediated in part by the tumor necrosis factor alpha (TNF-α). It 
has been reported that TNF-α enhances the apoptosis of chondrocytes and 
upregulates the levels of pro-resorptive cytokines that regulate the remodeling 
phase by osteoclasts (L. C. Gerstenfeld et al., 2003).  
The main source of the bone forming cells (osteoblasts) that repair the 
fractured bone during endochondral ossification remains controversial.  There 
are two different theories; the first one is that the fully differentiated 
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hypertrophic chondrocytes undergo programmed apoptosis and the progenitor 
cells from the blood vessels penetrate the cartilage callus which is undergoing 
degradation to replace the cartilage with bone. The second hypothesis is that 
some of the fully differentiated hypertrophic chondrocytes do not undergo 
apoptosis; however, they transdifferentiate into bone forming osteoblasts. 
Recent investigations using contemporary genetic lineage-specific tracing 
methods concluded the both pathways work parallel to each other. However, 
chondrocyte transdifferentiation into osteoblasts was the predominant pathway 
during the endochondral process (Bahney et al., 2014; X. Zhou et al., 2014). 
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Figure 2: A new endochondral ossification model for fracture healing. 
Stem cells from the periosteum and the endosteum will differentiate to form 
bone and cartilage forming cells. The early soft callus will be formed by the 
osteochondral progenitors differentiating into chondrocytes. Those 
chondrocytes undergo hypertrophic differentiation and will secrete potent 
angiogenic factors that result in the vascular invasion at the transitional zone 
which will facilitate the mineralization of the cartilage. Some hypertrophic 
chondrocytes will undergo apoptosis to create marrow space within the 
trabecular bone. Other hypertrophic chondrocytes regain some stem cell-like 
properties by expressing the pluripotent transcription factors OCT4, SOX2 and 
NANOG. These large cells re-enter the cell cycle, divide and then transform 
into osteoblasts. (Picture copied from Bahney et al., 2014) 
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Osteoclasts are the cells that normally line bones and are responsible 
for its resorption. Osteoclasts are large multinucleated cells that range 
between 150-200 µm in diameter. During fracture healing, osteoclasts resorb 
the cartilage within the healing callus. Receptor activator of NFκB Ligand 
(RANKL), Macrophage colony stimulating factor (MCSF), and Osteoprotegerin 
(OPG) are considered the key regulators of osteoclasts activation (Kon et al., 
2001). Cathepsin K is a member of peptidase C1 protein family which is 
expressed predominantly by osteoclasts and it is secreted into the resorptive 
pit. Cathepsin K is a protease that is capable of catabolizing type I collagen, 
elastin, and gelatin that enables the osteoclasts to resorb calcified tissue such 
as bone and cartilage. Once the osteoclast reaches the resorption site, 
cathepsin K is secreted into the resorptive pit from the ruffled border. It 
transmigrates by the intercellular vesicles with reactive oxygen species formed 
by TRAP to breakdown the ECM. A cathepsin K knock out mouse model 
showed an osteopetrotic phenotype. Osteopetrosis is defined as "stone bone” 
and it is also known as marble bone disease. It is a genetic disorder that 
affects the bone making it extremely dense and harder.  On the other hand, 
Osteoporosis is another more common condition in which the bone becomes 
very brittle and has a very low density. In osteopetrosis, the number of 
osteoclasts may be reduced, normal, or increased. Most importantly, 
osteoclast dysfunction mediates the pathogenesis of this disease.(Aker et al., 
2012) 
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While the cartilage is undergoing resorption, osteoblasts secrete bone matrix 
which undergoes calcification to form the woven bone which represents the 
bony callus (Dimitriou, Tsiridis, & Giannoudis, 2005). Bone morphogenic 
proteins are upregulated during this phase and they regulate osteoblasts 
recruitment, differentiation, and maturation (Cho et al., 2002). At the final stage 
of the fracture healing, this bony callus will remodel to the primary structure 
and morphology of the unfractured bone. Another set of cytokines are elevated 
during the remodeling phase including, but not limited to, TNF-α, IL-1 and IL-6 
(Kon et al., 2001).  
Diabetes Mellitus: 
Diabetes mellitus (DM) is a serious concern in the United States and 
worldwide as the incidence of this chronic disease has been rapidly increasing 
in the past 20 years. Today it is estimated that 415 million people worldwide 
are diagnosed with diabetes (IDF DIABETES ATLAS 6th edition 2015). DM is 
a disease characterized by high blood glucose level (hyperglycemia) due to 
insulin deficiency or due to the inability of the body cells to respond to the 
insulin secretion. There are two major types of diabetes mellitus, type 1(TIDM) 
and type 2 (T2DM).  
Type 1 is characterized by the destruction of Beta cells in the pancreas. The 
cause of type 1 diabetes is not known, although a number of possible 
hypotheses have been proposed. These predominant hypotheses are genetic 
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susceptibility, a diabetogenic trigger, and the exposure to an antigen. Type 1 
diabetes usually occurs following autoimmune response initiated by pancreatic 
inflammation and predominant infiltration of macrophages into the pancreatic 
islets (O'Reilly et al., 1991). Macrophages will stimulate the cytotoxic T-
lymphocytes which will secrete antibodies against beta cells (Jun, Santamaria, 
Lim, Zhang, & Yoon, 1999). They will also stimulate the production of a 
number of proinflammatory cytokines such as inertleukin-1β (IL-1β), interferon-
γ (IFN-γ), TNF-α. The combination of inflammatory cells infiltration and the 
production of the proinflammatory cytokines will lead to further destruction of 
beta cells promoting their apoptosis (Christen et al., 2001; Green, Eynon, & 
Flavell, 1998; Suarez-Pinzon et al., 1999; von Herrath & Oldstone, 1997). 
Type 2 diabetes is more prevalent and it is associated with very high 
insulin resistance. It has been reported that the incidence of type 2 diabetes is 
directly related to increased visceral adipogenesis (Colditz et al., 1990; Kahn & 
Flier, 2000; Mokdad et al., 2003). Adipocytes can release molecules that alter 
the insulin response by the body, which will enhance the insulin resistance. 
(Greenberg & Obin, 2006). During the early onsets of type 2 diabetes, the 
pancreatic beta cells will overproduce insulin to compete with the body’s 
resistance. This hyperinsulinemia usually leads to an increase in pancreatic 
cell mass (Dickson & Rhodes, 2004). Thus, these individuals do not develop 
diabetes. However, in many cases, the beta cell mass will undergo apoptosis. 
This results in the inability of the body to compensate for the insulin resistant 
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status and subsequently will result in sustained hyperglycemia leading to a 
diagnosis of type 2 diabetes. Thus, type 2 diabetes is characterized by both 
insulin resistance coupled with insufficient production of insulin to overcome 
the insulin resistance (Donath, Storling, Maedler, & Mandrup-Poulsen, 2003).   
Furthermore, a less common form of diabetes is gestational diabetes. 
Some pregnant women may undergo temporary changes in their metabolism 
including lowering their insulin sensitivity. The reduced insulin sensitivity will 
result in glucose intolerance. This condition is called gestational diabetes 
mellitus and it is defined as glucose intolerance first recognized in pregnancy 
(Dornhorst & Beard, 1993). The epidemiological studies of gestational 
diabetes show that it is widely variable and ethnicity-dependent. A family 
history of diabetes, as well as the maternal weight were all considered as 
predisposing factors to gestational diabetes (H. King, 1998; Xiong, Saunders, 
Wang, & Demianczuk, 2001). 
Diabetic complications: 
Mechanisms of Diabetic Complications 
Diabetes is associated with a number of reported factors that can lead 
to diabetic complications such as enhanced oxidative stresses, enhanced 
formation of advanced glycation end products (AGEs), increased the levels of 
protein kinase C activation (PKC), and shunting through the polyol pathway 
(Figure 3).  
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Diabetes is associated with downregulation of anti-oxidants as well as 
upregulation of superoxides (Giugliano, Ceriello, & Paolisso, 1996; Hunt & 
Wolff, 1991; Wolff & Dean, 1987). One of the negative impacts of 
hyperglycemia can happen through overloading the mitochondria. Once the 
mitochondria becomes overloaded its electron transport chains becomes 
dysregulated. This dysregulation leads to the release of electrons which react 
with oxygen and results in overproduction of superoxides, which will increase 
the oxidative stress inside the cell (Brownlee, 2005). It has been reported that 
the overexpression of reactive oxygen species (ROS) can harm cell 
membranes and can denature proteins. (Baynes & Thorpe, 1999). 
Furthermore, ROS can enhance the immune response through the activation 
and stimulation of cytokine secretions (Millar, Phan, & Tibbles, 2007; Mitra & 
Abraham, 2006). In addition, ROS was reported to be associated with 
enhancing inflammation by activating nuclear translocation of nuclear factor of 
kappa light chain gene enhancer in B-cells NF-κB (Gloire, Legrand-Poels, & 
Piette, 2006). 
Many reports showed that aging, obesity, and hyperglycemia are 
associated with enhanced formation of AGE’s (He, Koschinsky, Buenting, & 
Vlassara, 2001; He et al., 2000; G. L. King & Brownlee, 1996; Stitt & Curtis, 
2005; Vlassara & Bucala, 1996; Wada & Yagihashi, 2005; Yan, Ramasamy, 
Naka, & Schmidt, 2003). AGE’s can cause cross-linking of the cell membrane 
as well as denaturing proteins, which will result in altering many cellular and 
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molecular activities. (G. L. King & Brownlee, 1996; Stitt, He, & Vlassara, 1999; 
Vlassara & Bucala, 1996). AGE’s can also enhance the recruitment of different 
inflammatory cells including mononuclear phagocytes. Furthermore, AGE’s 
can also increase osteoclastic activities and facilitate bone resorption in 
cultured mouse bone cells (Miyata et al., 1997). Finally, it has been reported 
that AGE’s- RAGE combination blocked MSC differentiation to chondrocytes 
or osteoblasts and it enhanced the programed cell death (Kume et al., 2005). 
Hyperglycemia is a sustained state of excessive glucose levels inside 
the tissues. The excess glucose leads to the activation of the polyol pathway 
and subsequently elevates the levels of both sorbitol and fructose (Gabbay, 
1973). Shunting through the polyol pathway increases the production of 
AGE’s, ROS, and nitric oxide (NO) (Cameron & Cotter, 1992; Hamada, Araki, 
Horiuchi, & Hotta, 1996; G. L. King & Brownlee, 1996; Stevens et al., 1994).  
High glucose is associated with activating PKC, nuclear translocation of (NF-
κB), and dephosphorylating of the inhibitor of NF-κB kinase (IKK). Blocking 
aldose reductase in diabetic conditions blocks these effects (Ramana, 
Bhatnagar, & Srivastava, 2004a, 2004b; Ramana, Friedrich, Srivastava, 
Bhatnagar, & Srivastava, 2004; Ramana et al., 2005; Srivastava, Ramana, & 
Bhatnagar, 2005).  
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Figure 3: Mechanisms of diabetic complications. Hyperglycemia caused by 
diabetes leads to an increased oxidative stress, activation of the polyol 
pathway, the formation of AGE’s, and increased PKC activity. These factors 
increase proinflammatory cytokine expression, enhance PMN and monocyte 
recruitment, and impair bacterial killing. These alterations may contribute to 
complications seen in diabetes. 
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Diabetes and bone fractures: 
It has been reported that there is an increased risk of fractures of the 
long bones in patients with TIDM (odds ratio = 2.2) and T2DM (odds ratio = 
2.8) (Hernandez, Do, Critchlow, Dent, & Jick, 2012).  Furthermore, in T1DM 
the relative risk of hip fracture was 6.9 after adjusting for age, body mass 
index and smoking (Forsen, Meyer, Midthjell, & Edna, 1999; Vestergaard, 
Rejnmark, & Mosekilde, 2005). One of the possible mechanisms is through 
decreased bone mineral density and osteopenia. (Hamada et al., 2007; Jehle, 
Jehle, Mohan, & Bohm, 1998; Kemink, Hermus, Swinkels, Lutterman, & 
Smals, 2000; Piepkorn et al., 1997; Tuominen, Impivaara, Puukka, & 
Ronnemaa, 1999). Kemink et al. reported that 67% of diabetic men and 57% 
of diabetic women had osteopenia of either the femoral neck and/or the 
lumbar spine. They have also reported that the diabetic patients had a lower 
level of plasma insulin-like growth factor (IGF) in comparison to the normal 
control. Furthermore, they have indicated that within the diabetic group of 
patients, those who had femoral neck osteopenia had significantly lower 
plasma IGF-1 levels compared to those without osteopenia (Kemink et al., 
2000). The mechanisms of osteopenia caused by diabetes have been 
thoroughly investigated. In one investigation, they found that individual with 
type 1 diabetes had lower BMD and they found a drastic reduction in the 
serum levels of osteocalcin. Osteocalcin is a noncollagenous hormone 
secreted primarily by osteoblasts and odontoblasts in a vitamin K-dependent 
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process. Osteocalcin plays a major role in the mineralization of hard tissues in 
addition to its role in the homeostasis of calcium. Osteocalcin also behaves as 
a hormone that stimulates pancreatic cells to release more insulin into the 
system.  
 
 
 
Figure 4: Mechanisms of how diabetes reduces bone formation. The 
hyperglycemia caused by diabetes will enhance and prolong the inflammation 
status of the body which will enhance the formation of AGEs, ROS and 
reduction in insulin signaling. Those events will affect osteoblasts and will 
reduce bone formation via dysregulating BMPs, Runx2, or Fra1. Copied from 
(Jiao, Xiao, & Graves, 2015) 
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Another group of investigators suggested that the osteopenia caused 
by diabetes is not only due to decreased bone formation but, also as a result 
of increased bone resorption associated with IGF deficiency. They have 
measured urinary deoxy pyridinium crosslinks, which is a marker of bone 
resorption, in diabetic patients and they have reported that it was significantly 
upregulated compared to matched controls (Bjorgaas, Haug, & Johnsen, 
1999). Since type 1 diabetics are typically deficient in insulin, it has been 
proposed that the hypoinsulinemic status rather than the hyperglycemic effects 
of diabetes is the causative factor for bone dysregulation (Thrailkill, Lumpkin, 
Bunn, Kemp, & Fowlkes, 2005). However, a study on euglycemic mice, mice 
with tissue-specific insulin receptor deficiency, showed that those mice had 
normal bone mass. Besides, those mice had normal mRNA levels of both 
osteocalcin and runt-related transcription factor 2 (Runx2). All those findings 
indicate that osteopenia caused by diabetes is due to hyperglycemia rather 
than hypoinsulinemia (Irwin, Lin, Motyl, & McCabe, 2006). 
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Figure 5: Mechanisms of how diabetes increases osteoclastogenesis. 
Hyperglycemia caused by diabetes enhances inflammation and the production 
of AGEs, ROS, and will decrease insulin signaling. This will lead to alteration 
in the RANKL/OPG ratio which will increase osteoclast formation (Copied from 
(Jiao et al., 2015). 
  
 
 
18 
Streptozotocin-induced animal model: 
 Streptozotocin (STZ) induced diabetes is a commonly used animal 
model because it is straightforward and reproducible (Lenzen, 2008). STZ (2-
deoxy-2-(3-methyl-3- nitrosourea)-1-D-glucopyranose) is a broad-spectrum 
antibiotic synthesized by Streptomyces achromogenes. It has a structure that 
is similar to glucose and N-acetyl glucosamine (GlcNAc) which facilitate its 
transportation to the pancreatic β cells. This transport is exclusive by glucose 
transport protein GLUT2 but not by other transporters (figure 6). It has been 
reported that β cells have very high levels of GLUT2 which would explain the 
high toxicity of STZ on β cells (Schnedl, Ferber, Johnson, & Newgard, 1994; 
Z. Wang & Gleichmann, 1998). Once STZ is transported into the cells, it 
induces cell death through different suggested pathways. First, the formation 
of carbonium ions (CH3+) will result in activating poly ADP-ribose synthetase 
resulting in DNA methylation. The second pathway works via increased 
production of hydrogen peroxide and other free radicals that will promote the 
cell’s death. Finally, STZ might increase nitric oxide levels within the cells 
which will accelerate the cell death process. (Szkudelski, 2001; Tesch & Allen, 
2007) 
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Figure 6: Chemical structures of (A) glucose, (B) N-acetyl glucosamine 
and (C) streptozotocin  
Several studies using STZ-induced diabetes showed the negative 
impact of the disease on bone. There was a significant reduction in bone 
mineral density as well as bone mineral content in STZ induced diabetic 
animals. Moreover, the levels of osteocalcin in the serum were also 
significantly reduced compared to non-diabetic animals. (Botolin et al., 2005; 
Hou, Zernicke, & Barnard, 1991). Also, STZ induced diabetic animals had 
around 20-30% decrease in the biomechanical strength of both femurs and 
tibias (Hou et al., 1991; Reddy, Stehno-Bittel, Hamade, & Enwemeka, 2001). 
As previously mentioned, diabetes is associated with enhanced AGE’s 
production, and the role of upregulated AGE’s in diabetic complications is 
already well established. Santana and colleagues showed the association 
between higher levels of RAGE in diabetic animals and the reduction in bone 
forming capability of STZ-induced diabetic mice compared to the matched 
controls. Besides, there was a significant reduction in the bone forming ability 
A B C 
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upon treating normal animals with AGE’s to levels matching the diabetic 
animals (Santana et al., 2003). Alikhani et al. showed both in vitro and in vivo 
the upregulation in osteoblast apoptosis associated with AGE’s treatment 
which might explain the significant reduction in the bone forming capacity 
associated with AGE’s upregulation. In addition to increasing osteoblasts 
apoptosis, it has been reported that AGE’s were associated with increased 
osteoclastic activities through upregulating the production of the 
proinflammatory cytokine IL-6 (Miyata et al., 1997)  
Our lab has previously shown that diabetes causes premature cartilage 
resorption. Although the mechanism of how diabetes negatively affects the 
fracture healing is unknown, our lab has proposed a dominant mechanism 
which is the premature cartilage resorption via upregulation in osteoclastic 
activates. Our lab has shown that diabetes resulted in smaller cartilage areas 
at the transitional time. (Kayal et al., 2007). During fracture healing, there was 
double the number of osteoclasts in the calluses of diabetic animals compared 
comparison to normal animals. The striking change in osteoclast numbers was 
associated with significantly higher mRNA levels of RANKL in the diabetic 
animals (Kayal et al., 2007). Tsentidis et al. suggested a reduction in IGF1 as 
a mechanism of diabetes enhanced total s-RANKL (Tsentidis et al., 2016). Our 
lab has also shown that the diabetic-induced upregulated osteoclastogenesis 
was TNF-α dependent, and when the diabetic mice were treated with a TNF-α 
inhibitor, they exhibited normal osteoclastic activities. TNF-α upregulation in 
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diabetes may reduce the capacity to downregulate other inflammatory and 
apoptotic genes which have been linked to the reduction in bone coupling in 
diabetic animals. Prolonged overexpression of TNF-α leads to upregulation in 
nuclear factor-kappa-B activity and will diminish the levels of fra-1 and runx2 
which are potent stimulators for osteoblast migration, proliferation, and 
differentiation. Furthermore, TNF-α overexpression has been linked to the 
reduction in osteoblast numbers through increasing programed cell death via 
activating caspase 3 and altering Bax/Bcl-2 ratio (Coe, Irwin, Lippner, & 
McCabe, 2011). In another investigation, our lab has shown that diabetes 
causes upregulation of inflammatory cytokines and chemokines expressed by 
chondrocytes. The overexpression of those cytokines and chemokines might 
play an important role in the diabetic-induced impaired fracture healing. 
Furthermore, those cytokines and chemokines were mediated in part by the 
transcription factor forkhead box O1 (FOXO1) (Alblowi et al., 2013). 
FOXO1: 
Forkhead box (FOX) transcription factor was first found in Drosophila. It 
was then cloned and characterized in humans by homology. FOXO is a family 
of transcription factors involved in many cellular and molecular events. FOXO 
transcription factors are a member of a big family of forkhead proteins 
characterized by the presence of a winged-helix DNA binding domain called 
Forkhead box (Almeida, 2011). They are currently the largest family of 
transcription factors in humans, and they have been grouped according to 
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their structural characteristics into four subclasses; FOXO1 (or FKHR), 
FOXO3 (also known as FKHRL1), FOXO4 ( which is also called AFX) and 
FOXO6 (Greer & Brunet, 2005).  All the members of this subfamily are highly 
expressed in bone and cartilage forming cells, except FOXO6, which is 
expressed exclusively in the brain (Jacobs et al., 2003). It has been reported 
that these family members are key regulators in processing various stimuli 
such as inflammation, hormonal changes, increased oxidative stresses and 
free radicals into different physiological and pathological events. Furthermore, 
FOXO1 activities regulate several genes that control glycogenesis and 
gluconeogenesis.  
  
 
 
23 
 
 
 
 
 
 
 
Figure 7: Mechanisms of FOXO1 activation. FOXO1 translocate into the 
nucleus in the absence of insulin which will lead to activation of all the FOXO1 
dependent cascades. (picture copied from Current Biology) 
Insulin plays a major role in regulating FOXO1 activities since the 
deactivation of this transcription factor is mediated by the insulin/PI3K/AKT 
signaling pathway. Several pathways are activated through insulin receptor 
signaling. One of those pathways is Ras which will activate MAP kinase. 
Furthermore, insulin also induces the phosphorylation of insulin receptor 
substrate 1 (IRS-1) and IRS-2 and the activation of phosphatidylinositide-3-
kinase (PI3K), which will subsequently activate AKT. Insulin resistance can 
lead to the reduction in the phosphorylation of IRS-1/IRS-2. The reduction in 
IRS-1 and IRS-2 activities will reduce PI3K activities and will increases MAP 
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kinase activation. AKT signaling regulates the activation of FOXO1 and is 
critical in controlling homeostasis. FOXO1 is deactivated by phosphorylation 
via AKT and SGK1 at three different sites. The phosphorylation process of 
FOXO1 reduces the DNA binding activities of this transcription factor and will 
facilitate its transport outside the nucleus to the cytoplasm, which will result in 
the inhibition of FOXO-dependent transcriptional activities. Acetylation of 
FOXO1 has been associated with the reduction in its activities (Lalmansingh, 
Karmakar, Jin, & Nagaich, 2012; Tikhanovich, Cox, & Weinman, 2013). On the 
contrary, deacetylation of FOXO1 increases its activities. It has been reported 
that members of the sirtuin family of deacetylases, silent information regulator 
-1 (Sirt-1) and Sirt-2, increase the transcriptional and DNA binding activities of 
FOXO1 via deacetylation. (Kobayashi et al., 2005)  
 Our lab has shown that there was a significant elevation in FOXO1 
DNA binding activities in diabetic fracture calluses. When TNF-α was inhibited 
by pegsunercept treatment, FOXO1 nuclear translocation diminished (Alblowi 
et al., 2009). Furthermore, high glucose inhibits FOXO1 binding to certain 
promoters and causes FOXO1 to elevate the expression of cytokines that 
interfere with healing (Zhang et al., 2015). 
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Specific Aims: 
Diabetes mellitus is a common chronic disease that affects more than 230 
million people worldwide. A significant complication of diabetes is impaired 
fracture healing (Cozen, 1972; Herskind, Christensen, Norgaard-Andersen, & 
Andersen, 1992; Loder, 1988). Long bone fractures heal primarily by 
endochondral bone formation. Chondrocytes deposit cartilage to form a soft 
callus, which also acts as an anlagen for later bone formation (L. C. 
Gerstenfeld et al., 2002). We have proposed that diabetes interferes with 
fracture healing by causing premature loss of cartilage through upregulation of 
osteoclast activity. This concept was supported by findings that the number of 
osteoclasts was doubled in the calluses of diabetic animals in comparison to 
the normal animals and coincided with the upregulation of pro-inflammatory 
and pro-apoptotic factors including TNF-a (Alblowi et al., 2013; Kayal et al., 
2007). 
Based on findings that TNF-a induces FOXO1, we tested the 
hypothesis that Foxo1 deletion in chondrocytes will improve the bone 
healing in diabetic mice by regulating the expression of a critical pro-
osteoclastogenic factor, RANKL. To investigate whether FOXO1 activation in 
chondrocytes is a critical factor in diabetes-impaired fracture healing we 
examined mice with lineage-specific deletion of FOXO1 in chondrocytes and 
determined the impact on fracture repair in diabetic animals. 
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Materials and methods: 
Animal model and Induction of diabetes: 
Cre recombinase is an enzyme from the integrase superfamily that 
uses a mechanism similar to topoisomerase to produce a lineage-specific 
recombination. Specifically, it catalyzes the site-specific recombination 
between the LoxP sites on both ends. The result of this recombination at the 
specific sites depend on the sequence and the location of the LoxP sites. The 
DNA that is located between the two floxed sites will be excised which will 
drive tissue specific or site specific gene deletion. 
All Animal experiments were conducted in conformity with the 
University of Pennsylvania Institutional Animal Care and Use Committee. In 
the current study lineage-specific FOXO1 deletion in chondrocytes was 
obtained by crossing mice with floxed FOXO1 alleles, provided by Ronald 
A.DePhino (MD Anderson Cancer Center) as previously described in the 
literature (Paik et al., 2007), with mice expressing Cre recombinase under the 
control of col2α1 (obtained from the Jackson Laboratory). This breeding 
scheme produced the experimental Col2α1Cre+/FOXO1L/L and Col2α1Cre-/ 
FOXO1L/L which were used as controls. Between two to five mice were housed 
per cage under standard conditions with a 14-hours light/ 10-hours dark 
cycles. All procedures were done on adult mice between the age of 10-16 
weeks. Mice were rendered diabetic by intraperitoneal (I.P) injections of 
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streptozotocin (50mg/kg) (Sigma, St. Louis, MO) in 10mM citrate buffer once 
every day for 5 consecutive  days (Graves et al., 2005). Control mice were 
injected with 10mM citrate buffer alone. Blood glucose was measured weekly 
from blood obtained from a small laceration in the tail. The weight of the mice 
was monitored as well as the mice hydration status. Mice were considered 
diabetic when blood glucose levels exceeded 250 mg/dl for two consecutive 
measurements. Mice typically become diabetic after 10 days from starting the 
injections. If animals did not develop hyperglycemia after the first round of 
injections, they were given a second round of STZ and if they still did not 
respond they were euthanized. Experiments were carried out when mice had 
been diabetics for at least 3 weeks. 
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Figure 8: The mouse model and the breeding scheme. An Illustration 
of the mouse model and the breeding scheme used in the study utilizing 
Cre lox system. Col2α1 promoter was used to drive FOXO1 deletion. 
Femoral fracture: 
An incision was made lateral to the knee and the tendon for the 
quadriceps femoris muscle was pushed medially to expose the articular 
surface of the femur. A 27-gauge needle was used to gain access to the 
medullary canal and a 30-gauge spinal needle was inserted for fixation. After 
suturing the incision, a controlled closed simple transverse fracture was 
created by blunt trauma using a guillotine device. The animals were 
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euthanized and femurs were harvested at 3 different time points: day 10, day 
16, and day 22 post fracture. The fracture sites were evaluated physically and 
radiographically at euthanasia time. All the fractures that weren’t mid-
diaphyseal or the grossly comminuted fractures were excluded from the study. 
An illustration of the study time line is presented in figure 9. 
Micro-Computed Tomography and Image Analysis: 
To evaluate the total callus and the bone volume, the fractured femurs 
were scanned individually using a desktop micro-computed tomography 
system (Scanco µCT40, Scanco Medical, Basserdorf, Switzerland). The scan 
axis coincided nominally with the diaphysial axis, 70kVp and 114mA were 
used to scan the samples. The integration time was 200ms with 19µm voxel 
size. Constrained, 3-D Gaussian filter (sigma=0.8, support=1) was used for 
noise reduction. A fixed, global threshold was chosen that represented the 
Figure 9: Study time line illustration showing the animal distribution and the 
different study groups. 
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transition in X-ray attenuation between the mineralized and the unmineralized 
tissue. The 3D reconstruction and the image data were analyzed using 
software provided by the system manufacturer to quantify the bone volume of 
the fracture callus using the same threshold. 
Histology and Histomorphometric Analysis:  
The harvested femurs with a small amount of surrounding muscle and 
soft tissues were fixed for 24 hours in cold 10% paraformaldehyde followed by 
decalcification in 10% EDTA (Boston Bioprodicts, Worcester, MA) for 5 weeks. 
The internal fixation pin was removed and the samples were then processed in 
ascending ethanol concentrations. After processing, the pieces were 
embedded in paraffin, sectioned at 4 microns and prepared for staining.  
Sectioning and histomorphometric measurements were performed according 
to methodologies described  in (L. C. Gerstenfeld, Wronski, Hollinger, & 
Einhorn, 2005).  Cross-sectional transverse sections were sampled along the 
long axis of the bone including the fracture site itself.  The callus area, 
cartilage area, and new bone area were measured in sections stained with 
safranin-O/fast green. The area of each tissue was assessed by computer 
assisted image analysis using NIS elements AR software (Nikon).  
Measurements were made by one examiner under blinded conditions, with the 
results confirmed by a second blinded examiner. 
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Safranin-O/Fast Green Stain: 
Slides were baked, deparaffinaized in xylene and hydrated in graded 
ethanol series from 100 to 80% for 2-3 minutes each. To stain the nuclei, 
slides were placed in Harris modified hematoxylin (Fisher Scientific, Fair Lawn, 
NJ) for 30 seconds then rinsed in slow running water for at least 5 minutes. 
Fast green (Fisher Scientific, Fair Lawn, NJ) was used as a background stain. 
The slides were placed in the stain for 7 minutes and then rinsed in 1% acetic 
acid for 1 second. After that, slides were placed in safranin-O (Sigma-Aldrich, 
St. Louis, MO) for 10 minutes to stain the cartilage. This was followed by 
dehydration in which slides go through graded series of ethanol from 80 to 
100% and then placed in xylene until cover slipping. 
Mechanical testing: 
A separate set of mice were utilized for mechanical testing. The mice 
were euthanized 5 weeks post-fracture to evaluate the mechanical properties 
of the broken femur at the remodeling phase.  Both the experimental and the 
contralateral femurs were harvested. The femurs ends were cemented and 
torsional testing was carried out on a servo hydraulic testing machine (MTS 
Corp., Minneapolis, MN) using a 20 Nm reaction torque load cell (Interface, 
Scottsdale, AZ). Femurs were tested to failure at an actuator head 
displacement rate of 1°/second. Max torque, stiffness, toughness, and 
modulus of rigidity were tested according to the method described by 
Manigrasso and O’Connor 2004. For each parameter, the means and 
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standard deviations were calculated.  
TRAP staining: 
Osteoclast formation was determined by counting the number of 
multinucleated, tartrate-resistant acid phosphatase (TRAP) positive cells lining 
cartilage. After deparaffinization and hydration, as previously mentioned, 
slides were placed in 0.2M acetate buffer for 30 minutes. The buffer was 
prepared from 16mg/ml of 0.2M sodium acetate (Sigma-Aldrich, St. Louis, 
MO) and 11.6mg/ml of 50mM tartaric acid (Sigma-Aldrich, St. Louis, MO) with 
a pH of 5.0. After 30 minutes, 0.5mg/ml naphthol AS-MX phosphate (Sigma-
Aldrich, St. Louis, MO) and 1.1 mg/ml fast red TR salt (Sigma-Aldrich, St. 
Louis, MO) were added to the solution and the slides were incubated at 37°C 
for 10 to 15 minutes. The slides were then placed in Harris modified 
hematoxylin (Fisher Scientific, Fair Lawn, NJ) for 30 seconds to stain the 
nuclei and rinsed in slow running water for 5 minutes. Slides were left over 
night to dry and cover slipped the next day. 
Immunohistochemistry in histological sections: 
To confirm the TRAP staining results, sections from formalin-fixed, 
paraffin-embedded samples were used for IHC staining using cathepsin K 
antibody. Deparaffinization and hydration were performed as mentioned above 
and antigen retrieval was performed using pressure cooker (2100-Retriever 
Aptum, Southampton, UK) at 120°C with 10mM of citric acid with a pH of 6.0. 
Samples were then blocked with avidin-biotin (Vector Laboratories, 
 
 
33 
Burlingame, CA) and nonimmune serum matching the secondary antibody. 
Slides were then incubated overnight with anti-cathepsin K antibody (Abcam: 
AB19027) at 4°C as well as a matched control IgG. The slides were then 
rinsed the next day and quenched with 3% hydrogen peroxide and incubated 
with biotin labeled secondary antibody (Santa Cruz Biotechnology, Santa 
Cruz, CA). Hematoxylin was used as a counter stain followed by slide 
hydration and cover slipping. Analysis of the cartilage was performed by 
comparison with safranin-O/fast green stained serial sections. Analysis was 
done blindly by one examiner with the results confirmed by a second blinded 
examiner.  
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Immunofluorescence in histological sections: 
Paraffin embedded slides were used for in vivo immunofluorescence 
assays. After deparaffinization and hydration, pressure cooker (2100-Retriever 
Aptum, Southampton, UK) was used at 120°C with 10mM of citric acid with a 
pH of 6.0 for antigen retrieval followed by non-specific binding blocking for 55 
minutes. Finally, an overnight incubation with anti-RANKL antibody (Santa 
Cruz sc9073) or anti-cleaved caspase 3 antibody (Cell Signaling Technology 
96615)  at 4°C as well as the appropriate isotype-matched negative control 
IgG was done. Primary antibody was localised by Biotinylated secondary 
antibody (Vector Laboratories). Avidin–biotin peroxidase enzyme complex 
(ABC) and tyramide signal amplification (TSA) were used to amplify the 
signals. Alexa Fluor 546–conjugated streptavidin (Invitrogen S-11225) was 
used to visualize the staining. Finally, the slides were mounted with DAPI 
(Sigma-Aldrich). Images were captured at different magnifications (4x, 20x, 
and 40x magnification) using a fluorescence microscope (ECLIPSE 90i; 
Nikon). The exposure time was set to the experimental group based on the 
IgG control signals. The quantification was performed with the aid of NIS 
Elements AR image analysis software. The percentage of positive cells was 
obtained by dividing the immunopostive cells over the total cell number 
measured by DAPI.  
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Primary Cell culture:  
Primary costal chondrocytes were isolated from (2-4 days old) 
experimental Col2α1Cre+/FOXO1L/L and control Col2α1Cre-/FOXO1L/L mice. 
Briefly the mice skin was dissected, the ribs were isolated, incubated in 
Pronase for 45 minutes to dissolve the soft tissue, followed by 60 minutes in 
Collagenase D to dissociate the hard tissue from the remaining soft tissues. 
Finally, the rib cage was incubated in Collagenase D for 3-5 hours to release 
the cells. Chondrocytes were cultured in DMEM media supplemented with 
10% FBS and 1% Antibiotic-Antimycotic (Thermo Fisher Scientific). 
 All cell cultures were maintained in a 5% CO2 humidified incubator at 37°C. 
Cells were put into starvation for 2 days (low serum media) followed by either 
serum stimulation for 14 hours or hypertrophic differentiation induction for 4 
days using DMEM with 10% FBS supplemented with 10mM β-
glycerophosphate and 50μg/ml ascorbic acid, RNA extraction was done using 
Quick-RNA Microprep kit (Zymo). Real-time quantitative RT-PCR of RANKL 
gene was performed. 
Reverse Transcription and Real Time PCR: 
 For a given experiment RNA was isolated from cells and 
SYBR® Green reverse transcription reagents (Applied Biosystems, Foster 
City, CA) was used for first-strand cDNA synthesis and amplification. Using a 
thermocycler, samples were incubated at 37°C for 60 minutes, followed by 
95°C for 5 minutes and then held at 4°C until transferred to -20°C for storage. 
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Real time PCR was done on StepOnePlus Real-Time PCR System using 10µl 
of master mix SYBR® Green gene expression assays (Applied Biosystems, 
Foster City, CA). Each experiment was performed three times and the results 
from the three separate experiments were combined in order to derive mean 
values and standard of error.  
In vitro Immunofluorescence:  
Primary chondrocytes isolated from Col2α1Cre+/FOXO1L/L and control 
Col2α1Cre-/ FOXO1L/L mice were seeded in 96-well plates. They were 
incubated in low glucose (5mM d-glucose), high glucose (25mM d-glucose) for 
5 days. In another set, cells were incubated with CML-BSA (200μg/ml) for 3 
days, which was prepared by chemical modification of BSA (Sigma-Aldrich) as 
previously described (Alikhani et al., 2010). The control cells were incubated 
with unmodified BSA. The cells were fixed for 10 minutes with 10% 
formaldehyde, permeabilized in 0.5% Triton X-100 for 5 min. Non-specific 
blocking was done with 2% nonimmune serum matching the secondary 
antibody followed by primary anti-RANKL antibody (Santa Cruz sc9073). 
Primary antibody was localised with biotinylated secondary antibody and Alexa 
Fluor 546–conjugated streptavidin and finally DAPI was used to stain the 
nuclei. Images were captured by a fluorescence microscope (Nikon Eclipse Ti) 
with the same exposure time for both the control and the experimental group. 
The mean fluorescence intensity (MFI) was measured using NIS Elements AR 
image analysis software. 
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TUNEL Assay: 
Apoptotic cells were detected by DeadEnd™ Colorimetric TUNEL 
System (Promega, WI, USA) which detects apoptotic cells by labeling and 
detecting DNA strand breaks by the TUNEL method. To distinguish apoptotic 
chondrocytes from other cells the images were combined with bright-field 
channel to confirm the cell morphology. In addition, stain was compared with a 
saffranin-o/fast green stain to verify the location of the chondrocytes. Slides 
were first depraffinaized and hydrated in the same manner mentioned. Slides 
were then incubated at room temperature for 15 minutes in diluted proteinase 
K solution and then rinsed with PBS. This was followed by 5 minute incubation 
in endogenous oxidation blocking solution, which is 3% hydrogen peroxide, at 
room temperature and then rinsed in PBS. After that, slides were incubated at 
room temperature for 30 seconds  in equilibration buffer, then in working 
strength TdT enzyme for an hour at 37°C. Slides were then incubated in 
working strength stop/wash buffer for 10 minutes at room temperature, they 
were then rinsed in PBS and incubated in anti-digoxignenin conjugate for 30 
minutes at 37°C. Slides were rinsed again in PBS and mounted with DAPI to 
stain the nuclei.  
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Chromatin Immunoprecipitation Assay: 
Chromatin immunoprecipitation assays (ChIP) were carried out with 
ChIP It Kit (Active Motif) using approximately 1.5 x107 ATDC5 murine 
chondrogenic cells. Hypertrophic differentiation was induced for 6 days using 
DMEM/F12 media supplemented with 50µg/ml ascorbic acid and 10mM β-
glycerophosphate. Different groups of cells at 70 to 80% confluency were 
separately treated with TNF-α (20ng/ml) for 30 minutes, CML-BSA (200μg/ml) 
or unmodified BSA (200μg/ml) as a control for 3 days, and high glucose 
(25mM) for 5 days. ChIP was done following the manufacturer’s instructions. 
Formaldehyde was used to fix the cells, followed by a PBS wash and glycine 
to stop the fixation process. The cells were collected by scraping and pelleted. 
A Dounce homogenizer was used to lyse the cells and to release the nuclei. 
An enzyme was used to shred the chromatin followed by Anti-FOXO1 antibody 
(Santa Cruz Biotechnology, Inc.) or control polyclonal nonspecific IgG (Cell 
Signaling, Danvers, MA) incubation. Protein G-coupled beads were used to 
precipitate the antibodies. Quantitative real-time PCR for RANKL and 
caspase-3 promoter which has a consensus FOXO1 element, was performed 
in triplicates.  
Luciferase reporter assay: 
Transient transfection with luciferase reporter constructs was performed 
by  senior lab members, Dr Guangyu Dong and Citong Zhang, using 
Lipofectamine™ 3000 (Thermo Fisher Scientific) in 48-well plates as 
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described before (Zhang et al., 2015). Briefly, ATDC5 cells were incubated in 
low serum culture media for 5 days with 5 or 25mM d-glucose, or with CML-
BSA (200µg/ml) for 3 days, or TNF-α (10ng/ml) for 12 hours before running 
the assay. Cells were cotransfected with RANKL luciferase reporter (provided 
by Dr. Charles A. O’Brien, University of Arkansas for Medical Sciences, Little 
Rock, AR) (O'Brien, Kern, Gubrij, Karsenty, & Manolagas, 2002) or Caspase-3 
reporter together with pGL3 luciferase control vector, FOXO1ADA or 
(Addgene) plasmid (referred to FOXO1) that is constitutively transported to the 
nucleus, pcFOXO1 which is a wild type FOXO1, or pCMV control plasmid. 
Two days after transfection, cells were lysed, Firefly and Renilla luciferase 
activities were measured using Dual Luciferase Reporter Assay kit (Promega) 
according to the manufacturer’s instructions. Firefly luciferase activities were 
divided by Renilla activities to normalize for transfection efficiency. 
Experiments were performed two to three times with similar results. 
The role of FOXO1 in chondrocytes proliferation and differentiation: 
The number of proliferative and hypertrophic chondrocytes was counted 
in the healing callus in Saf/O stained slides to measure the cell density. 
Furthermore, Primary chondrocytes were extracted from experimental FOXO1 
deleted and normal WT neonates. Cells were incubated in serum free media, 
stimulated with serum for 14 hours and the expression of cell cycle genes was 
determined by quantitative qPCR. Another set of cells were used to measure 
the proliferation curve. Cells were grown for 5 days, live images were taken 
 
 
40 
every day and finally DAPI was used to stain the nuclei. The number of cells 
was quantified at each time point.  
To study the effect of FOXO1 on chondrocytes differentiation, primary 
cells were treated with differentiation media for 4 and 10 days, quantitative 
qPCR were performed to detect the expression of known differentiation 
markers. Another set of cells were cultured and Alician blue staining was 
performed at 0,4,7, and 14 days to evaluate the matrix formation abilities of 
the cells. The absorbance of the dye was detected using TECAN odometer. 
 
FOXO1 binding activities and nuclear translocation: ( ongoing 
experiment) 
To better understand how high glucose regulates FOXO1 activations. 
ATDC5 murine chondrogenic cells will be seeded in 6-well and 96-well plates. 
Hypertrophic differentiation will be induced using DMEM/F12 media 
supplemented with 50µg/ml ascorbic acid and 10mM β-glycerophosphate. 
Cells will be incubated in high glucose containing media with the use of the 
following; insulin, AKT inhibitor, TLR4 inhibitor, Sirt-1 inhibitor, HDAC inhibitor, 
N-Acetyl-L-cysteine, and L-NAME hydrochloride. To explore the effect of 
insulin, phosphorylation, acetylation and ROS on FOXO1 activation under high 
glucose conditions. 
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Nuclear protein will be extracted from the 6-well plates, and will be used to 
evaluate FOXO1 binding activities using FOXO1 Transcription Factor Assay 
Kit (Abcam).  
The 96-well plates will be used for immunostaining with FOXO1 antibody 
compared to matched IgG control. FOXO1 nuclear localization will be 
quantified. 
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Statistics:  
Statistical analysis between the groups were determined by analysis of 
variance, one-way ANOVA, Tukey’s post-hoc test to denote significance. P < 
0.05 was considered statistically significant. All the results are expressed as 
the mean ± SEM. (*) indicates a significant difference between normal and 
diabetic (P<0.05). (+) indicates a significant difference between the diabetic 
animals with FOXO1 deletion and the diabetic control group (P<0.05).  
For the in vitro experiments, Student’s t test was used for the 
comparison between the study groups. P < 0.05 was considered statistically 
significant. 
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RESULTS 
Diabetes validation: 
To establish that the animals were diabetic, blood was obtained from 
the tail of the animal and blood glucose was measured. The experimental 
group, which was treated with streptozotocin, had a mean blood glucose level 
of 322 mg/dl (STD ±58), while the control group, which had the vehicle alone, 
had a mean blood glucose level of 85 mg/dl (STD ±10). This indicates that the 
experimental group was rendered diabetic by streptozotocin and the control 
group remained normoglycemic. In addition, the blood glucose level was also 
measured at the euthanasia time to confirm the established findings.   
Validating the animal model: 
To confirm the presence or absence of Cre recombinase in the animals, 
genotyping was performed via PCR using both Cre and FOXO1 primers. 
Genomic DNA was obtained from the mice’s ears/tails before starting the 
experiment and the results were validated at the time of euthanasia.  
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Figure 10: Col2a1Cre deletes FOXO1 in Chondrocytes only. 
 (A) Electrophoresis of PCR amplified FOXO1 and Cre recombinase primers 
to establish genotyping for each animal. (B) Immunofluorescence of primary 
chondrocytes using Col2 specific antibody to confirm the cells’ phenotype. (C) 
Immunofluorescence staining of primary chondrocytes from WT and (D) 
FOXO1 deleted mice using FOXO1 specific antibody to confirm that the 
experimental chondrocytes didn't’ express FOXO1. (E) In vivo 
Immunofluorescence staining of fractured callus from both WT and FOXO1 
deleted mice using FOXO1 specific antibody to show the lineage-specific 
deletion. * indicates a significant difference between WT and FOXO1 deleted 
group using Students t-test. P<(0.05).  
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Histomorphometric Analysis: 
 Experiments were carried out focusing on the stage of cartilage 
removal and bone formation, days 10, 16, and 22 during fracture repair. Callus 
size and cartilage area were measured on transverse sections of fracture 
midline stained with safranin-O/fast green stain. The histomorphometric 
analysis of fracture callus showed that there was no significant difference 
between the cartilage areas of the normoglycemic, diabetic, and diabetic mice 
with FOXO1 deletion in chondrocytes 10 days post fracture (P>0.05).  On day 
16, the diabetic group had 77% less cartilage than the normoglycemic group 
(P<0.05), and FOXO1 deletion in chondrocytes of the diabetic animals 
increased the cartilage area by 369% (4.7 fold) (P<0.05) to match the values 
of the normoglycemic group (P>0.05; Figure 11). 
To evaluate the significance of premature cartilage resorption on the 
callus, the callus size and new bone formed area were measured. Fracture 
calluses of the diabetic control group were 43% smaller on day 16 and 37% 
smaller on day 22 compared to the normoglycemic control group(P<0.05). 
FOXO1 deletion in chondrocytes in diabetic animals significantly increased the 
callus size on day 16 by 64% and on day 22 by 52% when compared to 
diabetic control groups (P<0.05). This parameter was comparable to that of 
normoglycemic animals (P>0.05; Figure12). Newly formed bone area was also 
quantified histologically. Diabetes decreased new bone formation by 47% on 
day 16 and by 51% on day 22(P<0.05). FOXO1 deletion from the diabetic 
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animals increased the new formed bone areas at day 16 by 77% and at day 
22 by 96% (P<0.05) and this was comparable to that of normoglycemic groups 
(P>0.05; Figure 12). 
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Figure 11: Diabetes significantly reduces cartilage area prematurely, 
which is rescued by FOXO1 deletion in chondrocytes. Comparison of 
cartilage area between (A) normoglycemic, (B) diabetic control, and (C) 
diabetic with FOXO1 deletion using safranin-O/fast green stained sections to 
measure the area of cartilage within each callus. Data are expressed as mean 
± SEM. * indicates a significant difference between normal and diabetic 
(P<0.05). + indicates a significant difference between the diabetic animals with 
FOXO1 deletion and the diabetic control group (P<0.05)  
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Micro CT: 
The differences in callus size and bone formation in on day 16 and 22 
were confirmed by high-resolution µCT. On day 16 post fracture, the total 
callus volume of the diabetic group was 39% smaller and the bone volume 
was 29% smaller compared to the normoglycemic group (P<0.05). On the 
other hand, FOXO1 deletion from chondrocytes in diabetic animals increased 
the total volume by 59% and the bone volume by 33% (P<0.05), to volumes 
similar to that of the normoglycemic group (P>0.05). The same trend was 
observed on day 22. When compared to the normal group, the diabetic group 
had 41% smaller total volume and 34% smaller bone volume (P<0.05). Upon 
FOXO1 deletion in the diabetic group, the total volume increased by 65% and 
the bone volume increased by 57%(P<0.05) to match the normoglycemic 
group (P>0.05; figure 12) 
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Figure 12: Premature cartilage resorption caused by diabetes resulted in 
significantly smaller callus and bone volume. FOXO1 deletion rescued 
the callus and the bone volume to normal levels. Comparison of callus size 
and new bone formation in in (A) normoglycemic, (B) diabetic control, and (C) 
diabetic with FOXO1 deletion using µCT scans and histology. The callus was 
defined as the area within the peripheral fibrous capsule, excluding the original 
cortical bone. Data are expressed as mean ± SEM. * indicates a significant 
difference between normal and diabetic (P<0.05). + indicates a significant 
difference between the diabetic animals with FOXO1 deletion and the diabetic 
control group (P<0.05)  
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Mechanical testing: 
To evaluate if the quality of the healed femurs is different among the 
study group, torsional mechanical testing was performed on a separate set of 
mice. The contralateral (non-fractured) legs were tested first, the results show 
that the base line values of both diabetic groups were identical. However, the 
mechanical testing of the experimental side showed that the diabetic control 
mice had significantly lower maximum torque to failure strength, stiffness, 
toughness, and modulus of rigidity compared to normal control mice. FOXO1 
deletion restored the max torque, the stiffness, and the modulus of rigidity to 
levels comparable to the normal control. 
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Figure 13: Diabetes significantly alters the mechanical strength of the 
healing callus. FOXO1 deletion restored the strength to normal levels. 
(A) Comparison of callus strength using torsional mechanical testing revealed 
that both diabetic groups had similar base line values. (B) Diabetic control 
mice had significantly lower maximum torque to failure strength, stiffness, 
toughness, and modulus of rigidity compared to normal control mice. FOXO1 
deletion restored the max torque, the stiffness, and the modulus of rigidity to 
levels comparable to the normal control. Data are expressed as mean ± SEM. 
* indicates a significant difference between normal and diabetic (P<0.05). + 
indicates a significant difference between the diabetic animals with FOXO1 
deletion and the diabetic control group (P<0.05) 
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Osteoclasts: 
In order to further investigate the process of cartilage resorption, the 
number of osteoclasts lining cartilage was measured on transverse callus 
sections stained with TRAP. The diabetic group had 2.8 times more TRAP 
positive cells lining cartilage than the normoglycemic group on day 10 
(P<0.05). The Diabetic group with FOXO1 deletion in chondrocytes had 4.5 
times less TRAP positive cells than the diabetic control group (P<0.05; Figure 
14). Furthermore, immunohistochemical staining using cathepsin K specific 
antibody was used to validate the osteoclast numbers obtained from TRAP 
stain. Ten days post fracture, the diabetic group had 4.4 times more cathepsin 
K positive cells lining cartilage than the normoglycemic group.  Diabetic group 
with FOXO1 deletion in chondrocytes had 6.5 times less cathepsin K positive 
cells than the diabetic control group (P<0.05; Figure 14). 
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Figure 14: Diabetes significantly increases osteoclasts formation, 
FOXO1 deletion reduced the osteoclasts numbers to normal level. 
Comparison of osteoclast numbers in (A,B) normoglycemic, (C)diabetic 
control, and (D) diabetic with FOXO1 deletion using TRAP stained sections. 
The obtained results were confirmed with cathepsin K IHC staining. Data are 
expressed as mean ± SEM. * indicates a significant difference between normal 
nd diabetic (P<0.05). + indicates a significant difference between the diabetic 
animals with FOXO1 deletion and the diabetic control group (P<0.05). 
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In vivo RANKL: 
To provide an insight into how FOXO1 expression by chondrocytes may 
regulates osteoclasts activation, quantitative analysis was performed to 
evaluate RANKL expression in chondrocytes by immunofluorescence using 
RANKL specific antibody compared to control IgG antibody. Diabetes led 
to 1.9-folds increased in the percentage of RANKL positive chondrocytes on 
day 10 and 1.7-fold increase on day 16 post fracture compared to the 
normoglycemic control group. On day 10 post fracture FOXO1 deleted group 
had 9 times less RANKL positive chondrocytes and on day 16 they had 23 
times less RANKL positive chondrocytes compared to the diabetic group 
(P<0.05; Figure 15). Those results indicate that diabetes enhances 
chondrocytes RANKL expression in the fracture calluses and the expression 
was mediated by FOXO1. 
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Figure 15: Diabetes increases chondrocytes’ RANKL expression which is 
FOXO1 dependent. Immunofluorescence images from (A) normoglycemic, 
(B)diabetic control, and (C) diabetic with FOXO1 deletion using RANKL 
specific antibody to evaluate the Chondrocytes’ RANKL expression in the 
fracture callus. (D,E) Quantitative data from day 10 and 16 post fractures. (HZ) 
Hypertrophic zone. Data are expressed as mean ± SEM. * indicates a 
significant difference between normal and diabetic (P<0.05). + indicates a 
significant difference between the diabetic animals with FOXO1 deletion and 
the diabetic control group (P<0.05). # indicates a significant difference 
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between the diabetic animals with FOXO1 deletion and the normal group. ** 
indicates a significant difference between the WT and FOXO1 KO. 
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In vitro RANKL expression : 
To investigate whether FOXO1 regulates RANKL expression in 
chondrocytes under diabetic conditions, primary chondrocytes were isolated 
from experimental Col2α1Cre+/FOXO1L/L and from control Col2α1Cre-/ 
FOXO1L/L newborn mice. The cells were cultured and quantitative qPCR 
analysis of RANKL mRNA levels was carried out after serum stimulation and 
differentiation induction. Chondrocytes with FOXO1 deletion had 46% less 
RANKL mRNA level at base line, 37% less RANKL expression after 14 hours 
of serum stimulation, and 54% less RANKL expression after 4 days of 
hypertrophic differentiation induction. 
Another set of isolated cells were incubated in high glucose and advanced 
glycation end product followed by immunofluorescence staining using RANKL 
specific antibody. Under high glucose condition, control group showed 62% 
increase in RANKL mean fluorescence intensity, FOXO1 deleted group 
showed 85% reduction in RANKL expression under low glucose and 69% 
reduction under high glucose treatment. Similar to the high glucose conditions, 
incubation with AGE led to 61% increase in RANKL expression in the control 
group compared to serum control incubation, FOXO1 deletion reduced RANKL 
expression by 82% under AGE incubation (Figure 15). 
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Figure 16:  In vitro diabetic conditions increase chondrocytes’ RANKL 
expression which is FOXO1 dependent In vitro RANKL expression was also 
evaluated using primary chondrocytes, isolated from control mice (WT) as well 
as experimental FOXO1 deleted mice (FOXO1 KO), treated with low glucose 
(LG) and high glucose (HG) containing culture media. Another set of cells 
were treated with advanced glycation end product (AGE) or unmodified bovine 
serum albumin. To better understand how FOXO1 modulate osteoclast 
formation by regulating chondrocytes’ RANKL expression. Primary 
chondrocytes precursor were isolated from Col2a1Cre+/FOXO1L/L (FOXO1 
KO) and from the wild type (WT) Col2a1Cre -/FOXO1L/L stimulated with serum 
for 14 hours or cultured in chondrogenic media to induce chondrogenic 
differentiation for 4 days as described in the materials and methods sections. 
(A) Quantitative RT-PCR analysis of RANKL mRNA levels at different time 
points. Data are expressed as mean ± SEM. * indicates a significant difference 
between WT and FOXO1 deleted group using Student T test (P<0.05).  
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Luciferase reporter, and ChIP assays: 
To verify the association and the possible regulation of RANKL by 
FOXO1, a luciferase reporter and ChIP assays were carried out. For the 
Luciferase reporter, ATDC5 cells were cotransfected with either FOXO1 
plasmid (FOXO1ADA) or vector. TNF-α, AGE, and high glucose doubled the 
RANKL luciferase relative expression with FOXO1 plasmid compared to the 
vector control. (Figure 17). 
In addition, Chromatin immunoprecipitation (ChIP) assays showed that 
FOXO1 interacted with the RANKL promoter under diabetic conditions. High 
glucose resulted in 10-fold enrichment of FOXO1 association with the RANKL 
promoter compared with control IgG precipitates. In addition, AGE resulted in 
13-fold, and finally TNF-α resulted in 33-fold enrichment. (Figure 17). 
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 Figure 17: Chondrocytes’ FOXO1 modulates diabetic fracture 
healing by regulating RANKL expression (A) The interaction of the 
RANKL promoter and FOXO1 was determined by quantitative real-time 
PCR of the pulled down chromatin using anti-FOXO1 IgG compared to 
matched control IgG. (B)  RANKL luciferase reporter assay after 
cotransfection with control (vector) or FOXO1 plasmid (FOXO1ADA). 
Data are expressed as mean ± SEM. * indicates a significant difference 
between (IgG and FOXO1antibody), and between (control vector and 
the FOXO1ADA) using Student’s T test (P<0.05). 
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Chondrocytes Apoptosis & cartilage degradation: 
 
To test wither premature cartilage resorption was the only mechanism 
of early cartilage loss in diabetic animals, chondrocytes apoptosis was 
measured using TUNEL assay was conducted at day 16 post fracture. In 
addition, cleaved caspase-3 expression by chondrocytes was detected using 
immunostaining. Finally, ChIP and luciferase reporter assays were performed 
using ATDC5 cells under different in vitro diabetic conditions to study the 
association between FOXO1 and caspase-3 promoter. We found that the 
number of apoptotic chondrocytes was significantly higher in the diabetic 
group compared to the normoglycemic. FOXO1 deletion reduced the number 
of apoptotic chondrocytes to normal levels. Furthermore, diabetic animals has 
50% more chondrocytes expressing caspase-3 compared to normal animals. 
FOXO1 deletion completely blocked the up-regulated expression of caspase-3 
caused by diabetes. In vitro experiment shows that there is a significant 
increase in FOXO1 binding activities to caspase-3 promoter under high 
glucose treatment and AGE treatment compared to IgG control. Finally, the 
luciferase reporter assay shows that FOXO1 regulates caspase-3 expression 
under in vitro diabetic model.  
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Figure 18: Diabetes significantly increases chondrocytes apoptosis and 
caspase-3 expression during fracture healing. FOXO1 deletion reduces 
both parameter to normal levels. (A) An immunofluorescence images of the 
IgG control. (B) An immunofluorescence images of the experimental group 
using TUNEL assay. (C) Quantified data showing that diabetic control mice 
has around 50% increase in apoptotic cells compared to normal group. 
FOXO1 deletion reduced it to normal levels. (D) An immunofluorescence 
pictures of the IgG control. (E) An immunofluorescence pictures of the 
experimental group using cleaved caspase-3 antibody. (F) Quantified data 
showing that diabetic control group has around 50% increase in caspase-3 
expressing chondrocytes compared to the normal group. FOXO1 deletion 
rescued caspase-3 expressing cells to levels similar to the normal group. (G) 
ChIP and Luciferase reporter assay shows that both high glucose containing 
media (HG) and AGE increases FOXO1 binding activities to Caspas-3 as well 
as regulating its expression at the transcriptional level. 
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The role of FOXO1 in chondrocytes proliferation and differentiation: 
 
The number of hypertrophic and proliferative chondrocytes was 
determined in the healing callus by counting the cells in Safranin-O stained 
sections. The number of cells was normalized by the measured area. FOXO1 
deletion significantly increased the number of the proliferative, but not the 
hypertrophic, chondrocytes in the healing callus. 
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Figure 19: FOXO1 deletion increases the number of proliferative 
chondrocytes in the healing callus. (A) The quantified data shows that 
FOXO1 deletion increases the number of proliferative chondrocytes compared 
to the normal control, in addition, FOXO1 deletion in diabetic animals 
increased the proliferative count over the wild type diabetic control. (B) The 
number of hypertrophic chondrocytes was no statistically different between the 
study groups.  
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Primary chondrocytes proliferation curve: 
WT and cKO cells were grown in DMEM with 5% FBS in 96-well plate 
pictures were taken for live cells during 0-4day and then fixed on the 5th day 
and stained with DAPI. 
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Figure 20: FOXO1 deletion enhances chondrocytes proliferation (A) An 
image of DAPI staining of primary chondrocytes isolated from both 
experimental (FOXO1 KO) and wild type control (WT) after 5 days in culture. 
(B) The proliferation curve of the primary cells shows a significant increase in 
cell proliferation upon FOXO1 deletion. 
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The expression of cell cycle genes in primary chondrocytes: 
To better understand how FOXO1 deletion increases chondrocytes 
proliferation. Primary costal chondrocytes were isolated from both the 
experimental mice and wild type control. The expression of different cell cycle 
genes after 48 hours of cell starvation followed by 14 hours stimulation with 
10%FBS was evaluated using quantitative real time PCR. 
 
Figure 21: FOXO1 deletion enhances chondrocytes proliferation via 
regulating cell cycle genes expression. qPCR results show the effect of 
FOXO1 on cell cycle gene expression. FOXO1 deletion decreases the 
expression of p21, p27 which are a potent down-regulator for cells 
proliferation. In addition, FOXO1 deletion significantly up-regulated CD1, CD2, 
and CDK1, which are critical phosphorylation of variety of proteins, leads to 
cell cycle progression. 
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The role of FOXO1 in chondrocytes differentiation: 
Primary costal chondrocytes from experimental mice and wild type control 
were isolated, cultured, and differentiated with differentiation medium (growth 
medium supplemented with 50 μg/ml ascorbic acid and 0.5 mM NaH2PO4). 
mRNA levels of differentiation genes were detected using qPCR. 
Alcain Blue staining was used for another set of cell to detect the matrix 
formation at different time points 0day, 4days, 7days, and 14days. The results 
show that FOXO1 deletion has no effect on chondrocyte differentiation or 
matrix formation ability. 
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Figure 22: (A) qPCR results show that FOXO1 deletion doesn’t alter the 
expression of different known differentiation markers. (B) Alician blue staining 
at different time point for both the experimental and the control group that 
shows similar matrix forming abilities. (C) Quantified data from the odometer 
shows comparable absorbance at all the studied time points. 
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Discussion 
 
Diabetes is a significant disease with many complications, particularly if 
left uncontrolled.  It has been reported that diabetes negatively affects the 
skeleton integrity and it impairs fracture healing process (Clarke, 2010; Saller, 
Maggi, Romanato, Tonin, & Crepaldi, 2008). STZ induced diabetes 
significantly affected the calluses in the current investigation. There was a 
significant reduction in the cartilage area at the transitional time point, which 
resulted in a significantly smaller callus volume and smaller bone volume 
within the healing callus. Several parameters were compared by Botolin and 
McCabe between STZ induced diabetic mice and non-obese diabetic (NOD) 
mouse model which develops type 1 diabetes mellitus spontaneously. Both 
animal models showed comparable bone character, and they both showed a 
reduction in bone trabeculation with increased marrow adipocytes. They also 
showed a similar reduction in osteocalcin mRNA in the tibia. (Botolin & 
McCabe, 2006). Furthermore, BB rats, which develop type 1 diabetes 
spontaneously, exhibited a comparable decrease in serum osteocalcin levels, 
bone mineral density, and mechanical properties to STZ induced diabetic mice 
(J Verhaeghe et al., 1989; J. Verhaeghe et al., 1990). Those findings validate 
the effect of multiple low dose STZ diabetic model on bone. 
The mechanism of how diabetes impairs the fracture healing is not 
entirely understood. It has been previously reported that the diabetic animals 
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had significantly smaller calluses than those in normal animals. Those 
investigations attributed the reduction in size to decreased cartilage and bone 
formation (Gooch, Hale, Fujioka, Balian, & Hurwitz, 2000; Topping, Bolander, 
& Balian, 1994; Tyndall, Beam, Zarro, O'Connor, & Lin, 2003). In our 
investigation, there was no significant difference in the cartilage areas of the 
study groups 10 days post fracture, which suggests that diabetes doesn’t 
significantly alter the cartilage formation phase. This finding was consistent 
with what was reported by Kayal et al, in regards to the expression of collagen 
I, II, or X which wasn’t significantly different between normal mice and diabetic 
controls which suggests that the overall anabolic rate of chondrocytes or 
osteoblasts is similar at that stage.  
Cartilage is critical for fracture healing because it acts as a stabilizer for 
the fractured bony segments maintaining their close proximity. It also acts as a 
template for bone deposition as well as providing essential cytokines, 
chemokines, and growth factors. In the current study, diabetic animals 
exhibited significantly smaller cartilage areas at day 16, which is a critical time 
point for the transition of the healing callus from cartilage to bone, compared to 
normal animals. The cartilage areas were restored to normal levels upon 
FOXO1 deletion in the diabetic animals. The histology and micro CT of both 
day 16 and 22 in this study showed the impact of premature cartilage 
resorption caused by diabetes on the fracture healing. Diabetic animals 
showed significantly smaller calluses and bone volumes compared to normal 
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animals, which was consistent with the finding of Kayal et al. and Alblowi et al. 
FOXO1 deletion in diabetic animals rescued both the callus and the bone 
volumes to normal levels. We can attribute those changes to the significantly 
smaller cartilage area in the diabetic mice at the transitional time point. Naik et 
al. showed that there was delayed fracture healing in old mice and it was 
associated with smaller cartilage areas in comparison to the young mice (Naik 
et al., 2009). Besides, insulin resistant mice with impaired fracture healing 
exhibited premature chondrocyte differentiation which resulted in smaller 
cartilage areas and subsequently smaller calluses (Shimoaka et al., 2004). On 
the other hand, FOXO1 deletion from chondrocytes in diabetic animals in our 
study resulted in the maintenance of the cartilage at the transitional time and 
led to a better overall healing assessed both radiographically and 
histologically. 
Inflammation is essential for normal long bone fracture healing but it is 
very important to be critically regulated temporally and spatially. The first stage 
of the healing process involves an inflammatory response which is critical for 
attracting cells and releasing certain molecules essential for the progression of 
the healing process. Furthermore, inflammation is also critical at the late bone 
remodeling phase which is highly regulated by the expression of IL-1 and IL-6 
(Kon et al., 2001). Kayal et al. reported that these cytokines were elevated at 
the transitional time point (day 16) which is the period of cartilage resorption, 
not the bone remodeling. This confirms the uncontrolled inflammatory status of 
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the diabetic calluses compared to normoglycemic and FOXO1 deleted mice. It 
is well established that inflammation is associated with increased osteoclast 
recruitment and bone resorption (Kindle, Rothe, Kriss, Osdoby, & Collin-
Osdoby, 2006; Yu, Huang, Collin-Osdoby, & Osdoby, 2004). Many studies 
have reported that diabetes was associated with increased 
osteoclastogenesis. Suzuki et al. reported that patients diagnosed with DM 
had higher TRAP serum level in comparison to healthy individuals. They have 
also indicated that those diabetic patients had higher concentrations of Type 1 
Collagen Cross-linked Carboxy-terminal Telopeptide in their urine which 
confirms the increased resorption rate. (Suzuki et al., 2005). Maes and their 
group have shown that the cartilage was not effectively removed when the 
number of osteoclasts decreased during endochondral ossification (Maes et 
al., 2006). The opposite was observed in the current investigation, the diabetic 
animals had higher osteoclasts and cathepsin K positive cells lining cartilage 
consistent with the accelerated cartilage resorption observed in the diabetic 
animals. Our lab has also previously reported that there was an increase in 
TNF-α, MCSF, and RANKL in diabetic fracture healing (Kayal et al., 2007). 
These cytokines have been shown to induce the differentiation of bone 
marrow hematopoietic precursor cells into bone-resorbing osteoclasts 
(Cappellen et al., 2002). It has been shown that diabetes upregulates the TNF-
α related protein (TRAIL). TRAIL enhances chondrocyte apoptosis and it 
blocks osteoclast inhibition effect of OPG (Emery et al., 1998). Furthermore, 
 
 
82 
TNF-α stimulates the osteoblast expression of both MSCF and RANKL which 
will indirectly activate the osteoclastogenesis (Cenci et al., 2000; Kaplan, 
Eielson, Horowitz, Insogna, & Weir, 1996). Our lab previously examined the 
mechanism of how diabetes accelerates cartilage resorption through mRNA 
profiling and GSEA during the cartilage resorption stage of fracture healing. 
We have found that diabetes upregulated couple of TNF-α dependent 
inflammatory pathways which were associated with activation and maturation 
of osteoclasts (Alblowi et al., 2009). Those inflammatory pathways were 
mediated in part by FOXO1. FOXO1 deletion from chondrocytes in the current 
investigation resulted in the reduction of the number of osteoclasts lining 
cartilage as well as cathepsin K positive cells. This reduction of 
osteoclastiogenesis resulted in preserving the cartilage for a longer time to set 
the stage for bone deposition. 
MMP13 is one of the matrix metalloproteinases superfamilies. Its active 
enzyme is collagenase 3 which is secreted in its inactive form. It gets activated 
when its pro-domain cleaved. It has been reported that MMPs are involved in 
the breakdown of the extracellular matrix of cartilage and, to a lesser extent, 
bone, which can be explained by the superior ability of this gene to cleave type 
II collagen more efficiently than types I and III. Kayal et al. have previously 
reported that there was no difference between normoglycemic and diabetic 
animals in mRNA levels of MMP13 at the transitional time point (day 16), 
which is highly expressed during fracture healing and plays a major role in 
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cartilage remodeling (E. R. Lee, 2006; Yamagiwa et al., 1999) This finding 
might indicate that the quality of the cartilage was not affected by diabetes and 
the increased osteoclastic activities were the dominant mechanism explaining 
the accelerated cartilage lost observed in diabetic animals. 
It has been also reported that different inflammatory cytokines are 
involved in osteoclast activation. However, RANKL/OPG ratio was suggested 
to have the most and the final influential effect. (Hofbauer & Heufelder, 2001). 
The accelerated cartilage resorptions in the current investigation may be 
explained mechanistically by the increased number of osteoclasts in the 
healing callus which was directly proportional to the expression of RANKL by 
chondrocytes. Diabetic animals had almost 2 times more chondrocytes 
expressing RANKL in the healing callus compared to the 
normoglycemic control group. There was almost complete shutdown of 
RANKL expressions by chondrocytes upon FOXO1 deletion at all time points 
which indicate that RANKL expression was mediated by FOXO1 in the 
fractured callus. Gerstenfeld et al. also showed an increase of the residual 
cartilage in the healing callus when inflammation was inhibited by non-
selective anti-inflammatory drugs (L. C. Gerstenfeld et al., 2007). Thus, the 
retention of the cartilage by FOXO1 deletion in diabetic animals can be 
mechanistically explained by the reduction in the up-regulated inflammatory 
signals caused by diabetes, the reduced inflammatory status rescued the 
osteoclasts numbers to normal levels 
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The mechanism of diabetes and the lack of insulin during fracture 
healing has been controversially discussed in the literature. Our lab has 
previously shown that treating diabetic animals with insulin restored normal 
fracture healing on both tissue and molecular levels. Since insulin treatment 
resulted in significantly larger calluses and bone areas compared to non-
insulin treated diabetic animals. In addition, the osteoclastic activities, as well 
as tissue degradation markers were all significantly reduced to normal level 
upon insulin treatment. This was suggestive that the defect in healing process 
noticed in diabetes was a direct result of hyperglycemia. The anabolic effect 
on both bone and cartilage has been proposed by many groups. (Thrailkill et 
al., 2005). The negative impact of diabetes on the healing calluses were 
completely blocked by Gandhi and colleagues upon injecting insulin locally to 
the fractured bone (Gandhi, Beam, O'Connor, Parsons, & Lin, 2005). 
Nevertheless, local insulin delivery might be mediating its effect via 
upregulating IGF-1 activities, which is a potent stimulator for both bone and 
cartilage formation and does not necessarily represent the physiologic 
conditions (Irwin et al., 2006). Our results are also in agreement with this 
finding since both the diabetic control animals and the diabetic mice with 
FOXO1 deletion both lacked insulin, however the reduction in the inflammatory 
status mediated through FOXO1 deletion restored the impaired healing to a 
normal level. 
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The direct relationship between BMD and the mechanical loading on 
the skeleton is well established. The focus of the current investigation was 
directed toward better understanding and studying the effect of T1DM on 
bone. Individuals with T1DM are usually associated with nutritional deficits, 
low body weight, and lower BMD.  In contrary to TIDM, women and men 
diagnosed with T2DM usually have normal to high BMD in comparison to 
matched non-diabetic individuals. (Rakic et al., 2006; van Daele et al., 1995). 
People with lower Body Mass Index (BMI) have a higher risk of developing 
osteoporosis in addition to their increased fracture risk compared to matched 
peers. The increased BMD in patients with T2DM could be explained as a 
biomechanical adaptation of their body to the higher load they are subjected to 
since patients withT2DM have higher lean mass and higher weight compared 
to matched control. This biomechanical strain can induce bone formation in 
patients with T2DM.(Travison, Araujo, Esche, Beck, & McKinlay, 2008). As 
mentioned earlier, insulin is considered a potent anabolic factor for cartilage 
and bone formation, the hyperinsulinemic states observed in individuals with 
T2DM can also enhance the bone formation and will lead to increased BMD 
(Barrett-Connor & Kritz-Silverstein, 1996; Thrailkill et al., 2005). Adults 
diagnosed with T2DM are at higher risk of fracture despite their higher BMD. 
The mechanism is yet not fully understood. Diabetes is associated with a state 
of constant and chronic multisystem disruption. The changes in homeostatic 
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regulation might have a detrimental effect on bone and skeleton. The 
upregulation in the AGE’s could disturp the collagen cross-linking and alter the 
bone structure (Saito & Marumo, 2010; Viguet-Carrin et al., 2006; X. Wang, 
Shen, Li, & Agrawal, 2002). Furthermore,  bone turnover cycles might also be 
affected which will alter the microstructure of the bone marrow. Altered marrow 
might negatively impact the proliferation of MSC and their capability to 
differentiate into bone forming osteoblasts rather than adipocytes. It is well 
known that multiple factors regulate differentiation and maturation of MSC into 
its committed lineage(Sethe, Scutt, & Stolzing, 2006; S. Zhou et al., 2008). 
The swings in anabolic, catabolic, hormonal, and inflammatory status 
associated with diabetes could negatively impact MSC’s integrity which will 
increase the fragility of bones.(Cramer et al., 2010; Kassem, 1997; Kume et 
al., 2005) Thus, the bone mineral density should not be used solely to assess 
the fracture risk associated with diabetic patients. 
 
 
 
 
 
87 
 
 
Figure 23: Possible mechanisms of how type 2 diabetes might increases 
bone fragility and fracture risk. 
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Long bones are not the only bones associated with increased 
osteoclastogenesis, but also the alveolar bone, which supports the teeth in the 
mouth, had a higher resorption rate associated with diabetic animals 
compared to normal animals (Kohsaka, Kumazawa, Yamasaki, & Nakamura, 
1996; Villarino, Sanchez, Bozal, & Ubios, 2006). There was an upregulation in 
TNF-α, IL-1β, and the chemokine monocyte chemotactic protein 1 (MCP-1) in 
the serum and gingival crevicular fluid of patients with diabetes and they were 
associated with more severe periodontitis. Ligature-induced periodontitis is a 
well-established model to study periodontal disease. In this model, diabetic 
mice had a stronger and prolonged inflammation associated with increased 
osteoclastic activities, larger eroded bone area, reduced bone formation (Liu et 
al., 2006). Upregulated osteoclastogenesis was shown on a molecular level in 
a diabetic periodontal animal model. (Mahamed et al., 2005). 
Apical periodontitis (AP) is an inflammatory lesion which surrounds the roots of 
the teeth. It is caused by microbial invasion to the root canal system. The 
primary goal of any Endodontic therapy is the prevention or the treatment of 
AP. The prevalence of  individuals with AP associated with at least one tooth 
was reported be around 40-50%.(Saunders & Saunders, 1998). It has been 
reported that diabetic animals develop larger AP than non-diabetic controls.(A. 
Fouad, Barry, Russo, Radolf, & Zhu, 2002). In addition, human studies 
indicated a delayed healing of the AP lesions in diabetic individuals compared 
to normal individuals.(A. F. Fouad & Burleson, 2003). The mechanism of how 
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diabetes facilitates the development of AP or how it retards the healing has not 
been thoroughly investigated. This study might open the door to study possible 
different pathways and mechanisms using an STZ-induced diabetic animal 
model. The role of FOXO1, RANKL, and TNF-α in the development and 
healing of AP in diabetes will be my primary research interest in the near 
future. 
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CONCLUSIONS: 
v Diabetes has a significant effect on fracture healing by enhancing 
premature cartilage removal via up-regulating the osteoclastic activities. 
v Premature cartilage resorption resulted in smaller calluses and bone 
volume at later time points. 
v Chondrocytes are a major source of RANKL which was FOXO1 
dependent.  
v Lineage specific FOXO1 deletion down-regulated the 
osteoclastogenesis in diabetic animals to normal levels and the 
premature loss of cartilage was completely reversed. 
v We demonstrated, for the first time, that all the negative impacts from 
diabetes on callus size and bone formation were completely blocked 
when the cartilage was maintained to the right time. Furthermore, this is 
the first time it has been shown that FOXO1 modulates RANKL levels, 
which led to alteration in the up-regulated osteoclastogenesis. 
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Supplemental Experiments  
The role of FOXO1 deletion in the development and the maturation of the 
growth plates:  
To study if the cartilage phenotype observed during fracture healing in the 
diabetic is specific to the cartilage forms during the healing process and not 
other types of cartilage, the growth plates of 7 days post-natal mice as well as 
adult mice were studied using Safranin/O fast green stain. The adult joint 
spaces were also scanned using high resolution micro CT to evaluate the 
bone volume and the total growth plate volume.  
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Supplemental Figure 1: (A,B) Safranin/O staining of a representative 
samples from both normal and FOXO1 deleted neonate. (C) FOXO1 deletion 
didn’t change the growth plates zones. 
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Supplemental Figure 2: (A) Safranin/O staining of a representative samples 
from both normal and FOXO1 deleted adult growth plates. The images shows 
no difference in the orientation of the chondrocytes and the size of the growth 
plates between both groups (B) Micro CT images for femoral heads that 
shows comparable sizes between the WT and FOXO1 deleted mice. (C) 
Quantified data showing no differences in the total volume (TV) and bone 
volume (BV) (D) Tibial plateau μ CT image and quantified data shows no 
significant difference between the study groups. 
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Ongoing experiments  
Collaborative work with Dr. Dodge: 
To study the effect of FOXO1 deletion on the mineralization of cartilage, 
paraffin imbedded sections from day 10 post fracture were stained with 
Masson’s Trichrome, Alician blue, and Picrosirius Red. Quantification of the 
stained sectioned will be carried on to study the differences between the 
groups.  
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Supplemental Figure 3: Fracture slides from day 10 stained with (A) 
Masson’s Trichrom (B) Picrosirius Red (C) Alician blue. 
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RNA sequencing: 
RNA was isolated from fracture calluses from 8 different study groups. 
NG WT and FOXO1 deleted, Diabetic WT and FOXO1 deleted on both day 10 
and day 16 post fracture the RNA was sent for RNA-Seq using next 
generation sequencing. In addition, RNA was isolated from both day 7 and day 
13 from NG WT and FOXO1 deleted mice to look at the temporal effect of 
FOXO1 deletion on cartilage maturation and degradation. 
Furthermore, primary chondrocytes isolated from WT control or FOXO1 
deleted mice were cultured and treated under different condition to study the 
role of FOXO1 in chondrocytes proliferation, differentiation, apoptosis, and 
angiogenesis under both normal condition and high glucose cultured media. 
RNA was isolated from those cells and sent for RNA-Seq using next 
generation sequencing.  
Chondrocytes trans differentiation:  
An in Vivo study is taking place to evaluate the chobdrocytes – 
osteoblast trans differentiation and wither; 1- diabetes alter this process, 2- 
FOXO1 mediate the trans differentiation process involved in the process. 
Linage specific labeling was achieved using ROSA tomato reporter mouse 
under the effect of Col2 promoter. 
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FOXO1 activation under high glucose and AGE conditions:  
To better understand how high glucose regulates FOXO1 activations. 
ATDC5 murine chondrogenic were seeded and hypertrophic differentiation 
was induced using DMEM/F12 media supplemented with 50µg/ml ascorbic 
acid and 10mM β-glycerophosphate. Cells were incubated in high glucose 
containing media with the use of the following; insulin, AKT inhibitor, TLR4 
inhibitor, Sirt-1 inhibitor, HDAC inhibitor, N-Acetyl-L-cysteine, and L-NAME 
hydrochloride.  Another set of cells were incubated with AGE or unmodified 
BSA control and were treated with the same inhibitors. To explore the effect of 
insulin, phosphorylation, acetylation and ROS on FOXO1 activation under high 
glucose conditions. Nuclear protein was extracted, western blot will be done. 
The 96-well plates will be used for immunostaining with FOXO1 antibody 
compared to matched IgG control. FOXO1 nuclear localization will be 
quantified. 
 
 
 
 
 
